Not enough volume to concern me that is a dump. The SP will do what ever it does in the lead up to the P3 results- you could argue dumping, accumulation or capping. We are only 9 days away from seeing if the FDA have any issues to raise in relation to the Phelan-McDermid IND application, and another 9 days after that the same for the Pitt Hopkins IND application. Both these indications fall under the Neurology division of the FDA so we may have no issues. Angelman is under the Psychiatry division which is totally seperate.
Ann: US patent to 2034 granted for Neuren's NNZ-2591 in autism, page-17
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.395(2.60%) |
Mkt cap ! $1.994B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $4.312M | 276.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 2131 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.61 | 2133 | 39 |
View Market Depth
| Last trade - 15.04pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |